Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient care

Psychiatry Research

Volumn 226, Issue 1, 2015, Pages 68-72

  Thompson, Carmela ^a   Steven P Hamilton, ^b   Catriona Hippman, ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Direct to consumer testing; Genetic counseling; Genetics; Mental illness; Pharmacogenetics; Psychiatric disorders

Indexed keywords

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIRECT TO CONSUMER GENETIC TESTING; GENETIC COUNSELING; GENETIC SCREENING; HEALTH CARE MANAGEMENT; HEALTH CARE SURVEY; HUMAN; MENTAL HEALTH CARE; PHARMACOGENETICS; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; ADULT; FEMALE; HEALTH PERSONNEL ATTITUDE; INFORMATION PROCESSING; MALE; MIDDLE AGED; PATIENT CARE; PROCEDURES; PSYCHIATRY; PSYCHOLOGY;

ADULT; ATTITUDE OF HEALTH PERSONNEL; CROSS-SECTIONAL STUDIES; DATA COLLECTION; FEMALE; GENETIC COUNSELING; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; PATIENT CARE; PHARMACOGENETICS; PSYCHIATRY;

EID: 84930384713     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.11.044     Document Type: Article

References (28)

1. Altar C.A., Hornberger J., Shewade A., Cruz V., Garrison G., Mrazek D. Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int. Rev. Psychiatry 2013, 5:509-533.
2. Austin J.C., Honer W.G. Psychiatric genetic counseling for parents of individuals affected with psychotic disorders: a pilot study. Early Interv Psychiatry 2008, 2(2):80-89.
3. Bassett A.S., Costain G. Clinical applications of schizophrenia genetics: genetic diagnosis, risk and counseling in the molecular era. Appl. Clin. Genet. 2012, 20:1-18.
4. Bloom D.E., Cafiero E.T., Jané-Llopis E., Abrahams-Gessel S., Bloom L.R., Fathima S., Feigl A.B., Gaziano T., Mowafi M., Pandya A., Prettner K., Rosenberg L., Seligman B., Stein A.Z., Weinstein C. The Global Economic Burden of Noncommunicable Diseases 2011, World Economic Forum, Geneva.
5. Costain G., Esplen M.J., Toner B., Scherer S.W., Meschino W.S., Hodgkinson K.A., Bassett A.S. Evaluating genetic counseling for individuals with schizophrenia in the molecular age. Schizophr. Bull. 2014, 40(1):78-87.
6. Cross-Disorder Group of the Psychiatric Genomics Consortium Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 2013, 45(9):984-994.
7. Dodson C. Knowledge and attitudes concerning pharmacogenomics among healthcare professionals. Personal. Med. 2011, 8(4):421-428.
8. Ferrari A.J., Charlson F.J., Norman R.E., Patten S.B., Freedman G., Murray C.J.L., Vos T., Whiteford H.A. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLOS Med. 2013, 10(11):e1001547.
9. Finn C.T., Wilcox M.A., Korf B.R., Blacker D., Racette S.R., Sklar P., Smoller J.W. Psychiatric genetics: a survey of psychiatrists' knowledge, opinions, and practice patterns. J. Clin. Psychiatry 2005, 66(07):821-830.
10. Haga S.B., Burke W., Ginsburg G.S., Mills R., Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin. Genet. 2012, 82(4):388-394.
11. Hall-Flavin D.K., Winner J.G., Allen J.D., Jordan J.J., Nesheim R.S., Snyder K.A., Drews M.S., Eisterhold L.L., Biernacka J.M., Mrazek D.A. Using a pharmacogenomic algorithm to guide the treatment of depression. Trans. Psychiatry 2012, 2:e172.
12. Hall-Flavin D.K., Winner J.G., Allen J.D., Carhart J.M., Proctor B., Snyder K.A., Drews M.S., Eisterhold L.L., Geske J., Mrazek D.A. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenetic Genomics 2013, 10:535-548.
13. Hicks J.K., Swen J.J., Thorn C.F., Sangkuhl K., Kharasch E.D., Ellingrod V.L., Skaar T.C., Muller D.J., Gaedigk A., Stingl J.C. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 2013, 93:402-408.
14. Hippman C., Lohn Z., Ringrose A., Inglis A., Cheek J., Austin J.C. "Nothing is absolute in life": understanding uncertainty in the context of psychiatric genetic counseling from the perspective of those with serious mental illness. J. Genet. Couns. 2013, 5:625-632.
15. Hoop J.G., Savla G., Roberts L.W., Zisook S., Dunn L.B. The current state of genetics training in psychiatric residency: views of 235 US educators and trainees. Acad. Psychiatry 2010, 34(2):109-114.
16. Hoop J.G., Lapid M.I., Paulson R.M., Roberts L.W. Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 "early adopting" departments of psychiatry. Journal of Clinical Psychiatry 2010, 71(6):745-753.
17. Inglis, A., Koehn D, McGillivray B, Stewart E, Austin, J. Evaluating a unique, specialist psychiatric genetic counseling clinic: uptake and impact, Clin Genet ePub April 28, 2014.
18. Kendler K.S. "A gene for" the nature of gene action in psychiatric disorders. Am. J. Psychiatry 2005, 162:1243-1252.
19. Kessler R.C., Heeringa S., Lakoma M.D., Petukhova M, Rupp A.E., Schoenbaum M., Wang P.S., Zaslavsky A.M. Individual and societal effects of mental disorders on earnings in the United States: results from the national comorbidity survey replication. Am. J. Psychiatry 2008, 165(6):703-711.
20. Lanktree M.B., Zai G., Vanderbeek L.E., Giuffra D.E., Smithson D.S., Kipp L.B., Dalseg T.R., Speechley M., Kennedy J.L. Positive perception of pharmacogenetic testing for psychotropic medications. Human Psychopharmacol. 2014, 29(3):287-291.
21. Miller Christine Making sense of genetic tests. Clin. Lab. News 2012, 38(1):15.
22. Müller D.J., Kekin I., Kao A.C., Brandl E.J. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int. Rev. Psychiatry 2013, 25(5):554-571.
23. Mrazek M., Koenig B., Skime M., Snyder K., Hook C., Black J., Mrazek D. Assessing attitudes about genetic testing as a component of continuing medical education. Acad. Psychiatry 2007, 31(6):447-451.
24. Salm M., Abbate K., Appelbaum P., Ottman R., Chung W., Marder K., Leu C., Alcalay R., Goldman J., Curtis A., Leech C., Taber K., Klitzman R. Use of genetic tests among neurologists and psychiatrists: knowledge, attitudes, behaviors, and needs for training. J. Genet. Couns. 2014, 23(2):156-163.
25. Substance Abuse and Mental Health Services Administration Results from the 2012 National Survey on Drug Use and Health: Mental Health Findings, NSDUH Series H-47 HHS Publication No. (SMA) 13-4805 2013, Substance Abuse and Mental Health Services Administration, Rockville, MD.
26. Sullivan P.F., Daly M.J., O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat. Rev. Genet. 2012, 13(8):537-551.
27. Table of Pharmacogenomic Biomarkers in Drug Labeling, 2014. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm.
28. Winner J.G., Carhart J., Altar A., Allen J., Dechario B A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov. Med. 2013, 16(89):219-227.